Key Takeaways
- The FDA approved Revtorpyk (gedatolisib) on July 14, 2026 for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, a group that had no PI3K-targeted drug before this.
- In the phase 3 VIKTORIA-1 trial, the three-drug regimen cut the risk of progression or death by 76% against fulvestrant alone.
- Gedatolisib is the only approved drug that blocks all four class I PI3K isoforms plus both mTOR complexes, a deliberately wide net.
The patients this is actually for
Most targeted breast cancer drugs come with a catch: your tumor has to carry the specific mutation the drug was built to attack. For the PI3K pathway, that mutation is in a gene called PIK3CA, and until now, if your tumor tested negative for it, “wild-type” in the jargon, there was nothing pathway-targeted to offer you. The signaling network still drove the cancer. There just was no key cut for that lock.
Revtorpyk, made by Celcuity, is approved for exactly that overlooked group. The full label: adults with HR-positive, HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer, after the disease has progressed on at least one line of endocrine therapy. It is given with fulvestrant, with or without palbociclib. It does not compete with the mutation-targeted drugs. It covers the people they were never meant to help.
Why the broad mechanism is the point
Here is the biology that makes a wild-type indication possible. Older PI3K drugs are precision instruments, they jam one mutated target and nothing else, so they need that mutation to be present. Gedatolisib does the opposite. It blocks all four class I PI3K isoforms, alpha, beta, delta, and gamma, and both mTOR complexes, mTORC1 and mTORC2, at once.
Cover the whole pathway and you no longer need a single mutation to aim at. That is the rationale for using it in tumors that test wild-type: even without one clean target, the drug shuts down the network the cancer relies on. It is the only approved inhibitor that reaches across the pathway this far.
What VIKTORIA-1 showed
The approval rests on the phase 3 VIKTORIA-1 trial, presented as a late-breaking abstract at the 2026 ASCO annual meeting. In PIK3CA wild-type patients, both gedatolisib combinations were tested against fulvestrant alone, a standard endocrine therapy, so the numbers show what the new drug adds.
| Regimen | Risk of progression or death vs fulvestrant alone |
|---|---|
| Gedatolisib + palbociclib + fulvestrant | 76% lower |
| Gedatolisib + fulvestrant | 67% lower |
A 76% reduction is a big number for a group that started with no targeted option at all. The two-drug arm, for patients who cannot take palbociclib, still landed at 67%, which matters for real-world tolerability.
Where it sits in treatment
Revtorpyk is a later-line drug. It comes in after endocrine therapy stops holding the disease back, and it works alongside existing agents rather than replacing them. Eligibility runs through biomarker testing first, confirming HR-positive, HER2-negative, PIK3CA wild-type status before anyone starts.
Celcuity has also said it plans to file in Q3 2026 for the PIK3CA-mutated group, using the mutant cohort of the same VIKTORIA-1 trial. So the wild-type approval may be the first indication for this drug, not the last. For how precision treatment is reshaping side-effect and survival math in another tumor, see our coverage of prostate cancer focal therapy.
Sources:
- Drugs.com, “FDA Approves Revtorpyk (gedatolisib)”
- Celcuity, “FDA Approval of REVTORPYK (gedatolisib)”
- AJMC, “FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer”
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.